Zosano, Asahi Kasei Pharma deal

Zosano granted Asahi exclusive rights in China, Japan, Korea and Taiwan to use Zosano's ZP Patch microprojection delivery technology to develop and commercialize a transdermal formulation of Asahi's once-weekly subcutaneous osteoporosis drug Teribone teriparatide. Zosano received $7.5 million in cash up front and is eligible for over $25 million in milestones, plus undisclosed royalties. Asahi plans to begin clinical trials in Japan next year for the transdermal formulation of parathyroid hormone ( hPTH 1-34). Japan approved the subcutaneous formulation last month. ...